Nephros (NEPH) Competitors $1.54 +0.02 (+1.32%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NEPH vs. OM, APT, MODD, CTSO, NXL, NTRB, ICAD, LUCD, BLAC, and CLGNShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include Outset Medical (OM), Alpha Pro Tech (APT), Modular Medical (MODD), Cytosorbents (CTSO), Nexalin Technology (NXL), Nutriband (NTRB), iCAD (ICAD), Lucid Diagnostics (LUCD), Bellevue Life Sciences Acquisition (BLAC), and CollPlant Biotechnologies (CLGN). These companies are all part of the "medical equipment" industry. Nephros vs. Outset Medical Alpha Pro Tech Modular Medical Cytosorbents Nexalin Technology Nutriband iCAD Lucid Diagnostics Bellevue Life Sciences Acquisition CollPlant Biotechnologies Outset Medical (NASDAQ:OM) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership. Does the MarketBeat Community prefer OM or NEPH? Outset Medical received 11 more outperform votes than Nephros when rated by MarketBeat users. However, 43.33% of users gave Nephros an outperform vote while only 39.34% of users gave Outset Medical an outperform vote. CompanyUnderperformOutperformOutset MedicalOutperform Votes2439.34% Underperform Votes3760.66% NephrosOutperform Votes1343.33% Underperform Votes1756.67% Which has more volatility & risk, OM or NEPH? Outset Medical has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Does the media prefer OM or NEPH? In the previous week, Outset Medical's average media sentiment score of 0.90 beat Nephros' score of 0.00 indicating that Outset Medical is being referred to more favorably in the media. Company Overall Sentiment Outset Medical Positive Nephros Neutral Which has stronger earnings & valuation, OM or NEPH? Nephros has lower revenue, but higher earnings than Outset Medical. Nephros is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOutset Medical$114.73M0.55-$172.80M-$2.76-0.44Nephros$14.24M1.14-$1.58M-$0.09-17.11 Do analysts recommend OM or NEPH? Outset Medical currently has a consensus target price of $4.50, indicating a potential upside of 271.90%. Nephros has a consensus target price of $5.00, indicating a potential upside of 224.68%. Given Outset Medical's higher probable upside, equities analysts plainly believe Outset Medical is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outset Medical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OM or NEPH more profitable? Nephros has a net margin of -6.86% compared to Outset Medical's net margin of -122.84%. Nephros' return on equity of -11.39% beat Outset Medical's return on equity.Company Net Margins Return on Equity Return on Assets Outset Medical-122.84% -164.92% -43.27% Nephros -6.86%-11.39%-8.30% Do insiders & institutionals believe in OM or NEPH? 41.1% of Nephros shares are held by institutional investors. 3.5% of Outset Medical shares are held by company insiders. Comparatively, 4.1% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryNephros beats Outset Medical on 10 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.23M$4.33B$5.10B$9.07BDividend YieldN/A41.46%4.90%4.21%P/E Ratio-17.1125.3791.0817.15Price / Sales1.1445.671,113.51116.81Price / CashN/A43.4642.2637.86Price / Book1.937.364.784.78Net Income-$1.58M$13.64M$119.77M$225.60M7 Day Performance-0.65%-2.82%-1.87%-1.23%1 Month Performance2.67%0.54%11.46%3.07%1 Year Performance-47.62%41.80%30.53%16.48% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros1.6973 of 5 stars$1.54+1.3%$5.00+224.7%-50.0%$16.23M$14.24M-17.1130Positive NewsOMOutset Medical2.5559 of 5 stars$1.10-1.4%$4.50+311.0%-79.0%$57.53M$130.38M0.00520APTAlpha Pro TechN/A$5.22-0.6%N/A+3.1%$57.42M$59.29M14.19120MODDModular Medical3.1757 of 5 stars$1.54-3.1%$5.00+224.7%-14.7%$53.42MN/A-2.5239News CoverageCTSOCytosorbents2.5563 of 5 stars$0.97-3.5%$2.00+105.2%-50.3%$53.29M$33.79M-2.81186Analyst ForecastPositive NewsGap DownNXLNexalin Technology1.3024 of 5 stars$3.87-2.3%$3.00-22.5%+806.9%$49.78M$162,078.00-6.193Positive NewsNTRBNutriband0.4069 of 5 stars$4.39+6.0%N/A+63.2%$48.76M$2.02M-5.8310Positive NewsGap UpICADiCAD0.2943 of 5 stars$1.83-6.4%N/A+10.9%$48.44M$18.94M-15.0067LUCDLucid Diagnostics2.139 of 5 stars$0.81+3.2%$3.63+347.3%-43.0%$48.10M$4.19M-0.6970News CoverageHigh Trading VolumeBLACBellevue Life Sciences AcquisitionN/A$11.26-0.5%N/A+7.6%$45.49MN/A0.00N/ACLGNCollPlant Biotechnologies2.7297 of 5 stars$3.67-0.5%$12.50+240.6%-35.3%$42.02M$10.96M-2.4070Positive News Related Companies and Tools Related Companies Outset Medical Competitors Alpha Pro Tech Competitors Modular Medical Competitors Cytosorbents Competitors Nexalin Technology Competitors Nutriband Competitors iCAD Competitors Lucid Diagnostics Competitors Bellevue Life Sciences Acquisition Competitors CollPlant Biotechnologies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEPH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
